Antimicrobial Resistance: A Growing Global Threat

The scale of the problem

Antimicrobial resistance — the evolution of bacteria, fungi, viruses, and parasites such that previously effective drugs no longer kill or inhibit them — is not a future threat. It is already here. The Global Research on Antimicrobial Resistance (GRAM) study, published in The Lancet in 2022, estimated that 1.27 million deaths in 2019 were directly attributable to bacterial AMR, with an additional 3.68 million associated deaths. That places AMR ahead of HIV/AIDS and malaria as a cause of death.

The trajectory is steeper than the current burden. The Review on Antimicrobial Resistance commissioned by the UK government and chaired by Lord Jim O'Neill projected in 2016 that, without coordinated action, AMR could cause up to 10 million additional deaths per year by 2050 and cost the global economy US $100 trillion in lost output. The U.S. CDC's Antibiotic Resistance Threats in the United States report estimates more than 2.8 million resistant infections and 35,000 deaths annually in the US alone.

WHO has classified AMR as one of the top ten global public-health threats facing humanity. It is the only one of those threats where the rate of decay is driven, in large part, by clinical and agricultural choices made every day at the prescriber and bench level.

What's driving AMR

Resistance is a natural evolutionary response to selection pressure, but the pressure has been amplified well beyond background by four interlocking drivers:

• Overprescription and inappropriate use in human medicine. CDC has estimated that roughly 30% of outpatient antibiotic prescriptions in the US are unnecessary — commonly for viral upper-respiratory infections that antibiotics cannot treat. Incomplete or sub-therapeutic courses leave behind partially-susceptible populations that selectively expand.
• Agricultural and veterinary use. Historically, the majority of antibiotic tonnage sold in the US has been distributed for use in food-producing animals (FDA ADUFA reporting). Sub-therapeutic doses used for growth promotion or routine prophylaxis create the conditions for resistance to emerge in zoonotic and commensal organisms, including some that are clinically relevant in humans (Salmonella, Campylobacter, ESBL-producing E. coli).
• Hospital and long-term-care transmission. High antibiotic exposure, dense patient populations, indwelling devices, and the movement of staff and equipment between rooms make healthcare facilities the most efficient amplifiers of resistant organisms. C. difficile, carbapenem-resistant Enterobacterales (CRE), and MRSA are all canonical examples.
• A thin discovery pipeline. Few novel antibiotic classes have been approved in the last two decades. Most recent approvals are modifications of existing scaffolds, and the commercial return on a new antibiotic — used briefly, then held in reserve — is poor enough that several developers have left the market.

How bacteria resist: the three mechanisms

Resistance at the molecular level falls into three broad categories. Most clinically important resistant phenotypes use one (or several) of them:

• Enzymatic inactivation. The bacterium produces an enzyme that destroys or modifies the drug. Beta-lactamases hydrolyze the beta-lactam ring of penicillins and cephalosporins; extended-spectrum beta-lactamases (ESBLs) extend that activity to third-generation cephalosporins; carbapenemases (KPC, NDM, OXA-48, VIM, IMP) inactivate carbapenems, the historic last-line beta-lactams. Aminoglycoside-modifying enzymes act analogously on aminoglycosides.
• Target modification. The drug's binding site is altered so the drug no longer fits. MRSA carries mecA (or the rarer mecC), encoding penicillin-binding protein 2a (PBP2a), which has low affinity for all beta-lactams. Vancomycin-resistant enterococci replace the D-Ala-D-Ala terminus of peptidoglycan with D-Ala-D-Lac (vanA, vanB). Mutations in gyrA/parC confer fluoroquinolone resistance; ribosomal methylation by erm genes confers macrolide-lincosamide-streptogramin B resistance.
• Efflux pumps. Membrane transporters actively expel the drug before it reaches a lethal intracellular concentration. RND-family pumps in P. aeruginosa and A. baumannii contribute to broad multi-drug resistance phenotypes.

A fourth, often-overlooked contributor is horizontal gene transfer: resistance determinants ride on plasmids, transposons, and integrons that move between species. A single conjugative plasmid can carry blaKPC, an aminoglycoside-modifying enzyme, and a fluoroquinolone-resistance gene simultaneously — producing a clinical isolate that is resistant to three drug classes from one transfer event.

biotech Rapid Identification at the Bench Prolex™ Staph Xtra — MRSA-capable latex in 20 seconds Differentiates S. aureus (and many MRSA strains) from coagulase-negative staphylococci in a single 20-second slide test. CE Marked, FDA-cleared. arrow_forward

The ESKAPE priority pathogens

The acronym ESKAPE, coined by Rice (J Infect Dis 2008), captures the six bacterial species responsible for the majority of resistant nosocomial infections — so named because they "escape" the killing action of commonly used antimicrobials. The WHO Priority Pathogens List for R&D and the CDC threat report overlap significantly with ESKAPE:

Pathogen	Hallmark Resistance	Typical Setting
Enterococcus faecium	Vancomycin (VRE), ampicillin	UTI, bacteremia, endocarditis
Staphylococcus aureus	Methicillin (MRSA), vancomycin-intermediate (VISA)	Skin/soft tissue, bacteremia, pneumonia
Klebsiella pneumoniae	ESBL, carbapenem (KPC, NDM)	Pneumonia, UTI, bacteremia
Acinetobacter baumannii	Carbapenem, multi-drug, pan-drug	ICU, ventilator-associated pneumonia
Pseudomonas aeruginosa	Carbapenem, fluoroquinolone, multi-drug	CF, burns, ICU, biofilm device infection
Enterobacter spp.	AmpC, ESBL, carbapenem	UTI, bacteremia, intra-abdominal

WHO further calls out carbapenem-resistant Enterobacterales, third-generation cephalosporin-resistant N. gonorrhoeae, and rifampicin-resistant Mycobacterium tuberculosis as critical or high priority.

Antimicrobial stewardship

Antimicrobial stewardship is a coordinated set of interventions designed to improve and measure appropriate antimicrobial use — the right drug, dose, duration, and route. The CDC's Core Elements of Hospital Antibiotic Stewardship Programs, the IDSA/SHEA joint guidelines, and The Joint Commission's accreditation standard (effective 2017) together establish what a US hospital program must contain: leadership commitment, an accountable physician and pharmacist co-leadership, action (e.g., facility-specific treatment guidelines, prospective audit-and-feedback, formulary restriction), tracking, reporting, and education.

The data on impact are unambiguous. Stewardship programs reduce inappropriate antibiotic use by 20–50%, shorten length of stay, lower C. difficile rates, and slow the emergence of resistance — without harming patient outcomes. Outpatient stewardship has lagged but is the focus of CDC's Be Antibiotics Aware campaign and a growing number of state-level programs.

"We cannot have effective stewardship without effective diagnostics. Empiric therapy without microbiology is just guessing — and guessing is what got us here." — paraphrased consensus, multiple IDSA stewardship guidance documents.

The diagnostic lab's role: diagnostic stewardship

Every empiric antibiotic course is a hypothesis. The diagnostic lab is the only function in the hospital that can confirm or refute it. Diagnostic stewardship — ordering the right test on the right patient, performing it rapidly and accurately, and reporting the result in a form clinicians can act on — is the operational complement to antimicrobial stewardship.

Three categories of lab capability matter most:

• Rapid organism identification. Latex agglutination tests resolve a Gram-positive cocci-in-clusters into S. aureus vs. CoNS in seconds at the bench; Lancefield grouping resolves a beta-hemolytic colony into Group A/B/C/F/G in 60 seconds. MALDI-TOF takes a colony to species-level ID in minutes. See our internal pages on Prolex™ Staph, Prolex™ Strep, and stocking a curated reference collection on Microbank®.
• Antimicrobial susceptibility testing (AST). Broth microdilution remains the reference method; disk diffusion and gradient strips are practical adjuncts. CLSI and EUCAST set the breakpoints; lab participation in a CAP or external proficiency program is required. AST drives the de-escalation from broad empiric coverage to targeted therapy — the single most impactful stewardship lever.
• Molecular resistance-gene profiling. Direct detection of mecA/mecC, vanA/vanB, blaKPC, blaNDM, blaOXA-48, and blaCTX-M shaves hours-to-days off the time-to-targeted-therapy. Isothermal NAAT methods such as LAMP can deliver results on positive blood cultures in well under an hour at the bench, without thermocyclers. See Optigene Genie® LAMP platforms and our companion post on isothermal NAAT with resistance gene profiling.

Maintaining a curated, well-organized in-house reference collection is foundational to all three. Verified QC organisms (NCTC/NCPF strains via Pro-Cult, stored on Microbank®) underwrite the validity of every ID and AST result that leaves the lab.

What lab directors can do this quarter

Three operational moves are within reach of most clinical labs without a capital purchase:

1. Audit empiric-to-targeted turnaround time. Measure the median time from positive Gram stain to first targeted antibiotic order. If it is more than 24–36 hours for routine isolates, identify which step (transport, plate read, AST, report) owns most of the delay.
2. Add a rapid resistance flag to the report. If mecA, vanA, or a carbapenemase gene is detected, surface that in the LIS comment field with a stewardship-team page, not just a numeric MIC.
3. Refresh the QC strain collection. A resistance-detection assay is only as good as the positive- and negative-control strains validating it. Reference collections must include current carbapenemase- and ESBL-producing isolates, not just the 25923/25922 standbys.

Frequently Asked Questions

References

1. Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655. PMID: 35065702.
2. O'Neill J (chair). Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. Review on Antimicrobial Resistance, HM Government & Wellcome Trust, May 2016.
3. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services.
4. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079-81. PMID: 18419525.
5. World Health Organization. WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: WHO; 2024.
6. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51-77. PMID: 27080992.

To talk through how rapid identification and resistance-gene profiling could fit into your stewardship program, contact info@pro-lab.us, browse the Prolex™ Staph and Optigene Genie® product pages, or book a call with a scientist.